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Background: Although artificial ulcers generally heal faster than Helicobacter pylori-related or nonsteroidal
anti-inflammatory drug-related peptic ulcers, endoscopic submucosal dissection (ESD)-induced gastric ulcers are
usually treated with a proton pump inhibitor (PPI) for 4–8 weeks. The effect of oral administration of a PPI for 1 week
on ESD-induced gastric ulcers has not yet been evaluated. In the present study, we evaluated the efficacy of oral
PPI for 1 week in patients with ESD-induced ulcers.
Methods: We selected 45 patients who underwent ESD for gastric mucosal tumors between June 2005 and July
2006 at Toyama University Hospital, and who met our inclusion criteria. All patients received omeprazole
intravenously for 2 days after ESD and then orally for 1 week to prevent bleeding. Twenty two patients received no
further omeprazole therapy (1-week group) and the rest received omeprazole orally for 7 more weeks (8-week
group). Follow-up endoscopy was performed at 1 day, 4 weeks, and 8 weeks after ESD. We compared the ulcer
healing rates between both groups.
Results: There were no significant differences between the groups in the ulcer-healing rate, because ulcers healed
in 22 (96%) and 20 (91%) patients from the 8-week and 1-week groups, respectively.
Conclusions: In our study, oral administration of omeprazole for 1 week was sufficient to achieve healing of
ESD-induced artificial gastric ulcers. A larger prospective trial will be required to confirm these findings.
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Endoscopic mucosal resection (EMR) is a promising
treatment for early gastric cancer because it is less inva-
sive than surgery. EMR has been widely used as a cura-
tive treatment for gastric mucosal tumors such as early
gastric cancer or adenoma [1,2]. Endoscopic submucosal
dissection (ESD) is a new EMR method that is now be-
ing used to cure early gastric cancer and adenomas in
Japan [3]. Because en bloc resection of gastric tumors is* Correspondence: shin-ya@nsknet.or.jp
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unless otherwise stated.crucial for an accurate histological diagnosis to confirm
complete resection, ESD is superior to EMR for treating
large lesions. Improvements in endoscopic equipment and
techniques have allowed en bloc resection of whole lesions
(regardless of lesion size or shape) to become possible
with circumferential cutting of the surrounding mucosa
using the ESD method [4-6]. This method allows the pre-
cise histopathological diagnosis of the resected specimen;
however, an ulcer induced by ESD is usually larger than
that one induced by standard EMR [5].
Artificial gastric ulcers heal faster than Helicobacter pylori
(H. pylori)-related or nonsteroidal anti-inflammatory drug
(NSAID)-related gastric ulcers. However, the management
of ulcers caused by ESD has not been fully investigated andThis is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
Table 1 Staging system of gastric ulcer
Stage Findings
A1 (active stage 1) Ulcer with mucus coating and marginal
elevation because of oedema
A2 (active stage 2) Mucus-coated ulcer with discrete margin
and less oedema than active stage 1
H1 (healing stage 1) Healing ulcer < 50% covered by regenerating
epithelium with or without covering folds
H2 (healing stage 2) Ulcer with a mucosal break, but almost
covered by regenerating epithelium
S1 (scar stage 1) Red scar with rough epithelialization and
mucosal break(s)
S2 (scar stage 2) White scar with complete re-epithelialization
English version of the ulcer staging system of Sakita and Fukutomi [11].
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are invariably administered to prevent bleeding and induce
rapid healing of these ulcers. Gastric ulcers induced by ESD
are usually treated with a proton pump inhibitor (PPI) for
4–8 weeks [8-10]. However, there is no consensus on the
optimal duration of the PPI treatment, and no study yet has
tested whether the use of a PPI for 1 week is sufficient to
heal ESD-induced gastric ulcers. Therefore, we compared
the healing rates of ESD-induced ulcers in patients who re-
ceived orally administered omeprazole for 1 or 8 weeks.
Methods
Study design and patients
Among patients who underwent ESD for gastric mucosal
tumors between June 2005 and July 2006 in Toyama Uni-
versity Hospital, we selected patients who met our inclu-
sion criteria and did not meet our exclusion criteria.
Indications for ESD included gastric adenoma or early gas-
tric cancer (well-differentiated or moderately differenti-
ated) of any size without lymph node involvement or other
metastasis at the time of diagnosis. Inclusion criteria in-
cluded the administration of 20 mg of omeprazole orally
for 1 or 8 weeks after intravenous administration of 20 mg
of omeprazole for 2 days after ESD. Exclusion criteria were
as follows: (1) a history of upper gastrointestinal surgery;
(2) serious complications, including cardiac, hematological,
renal, and/or hepatic disease; (3) the recent use of PPI, a
histamine 2 receptor blocker or a mucosal protective agent;
(4) concurrent gastric/duodenal ulcer (excluding healed ul-
cers); (5) current use of aspirin, NSAIDs or corticosteroids;
or (6) absence of written informed consent from a patient.
In all patients, ESD was performed using a needle knife
and a hook knife (Olympus Optical Co., Ltd., Tokyo,
Japan) with the injection of glycerin and hyaluronic acid
solutions. All patients were administered omeprazole
intravenously for 2 days after ESD and then orally for
1 week to prevent bleeding after ESD. However, because
there was no consensus on the optimal duration of the
PPI treatment, our hospital doctors had agreed to provide
the PPI treatment for a minimum of 1 week after ESD.
When this minimum treatment was chosen, the PPI treat-
ment duration was 1 week. The duration of the PPI treat-
ment was decided by each physician. Different treatment
durations were chosen and treatment was implemented
accordingly. To investigate the effect of the duration of
the PPI treatment, we selected patients who underwent
treatment for 1 or 8 weeks for this study. Thus, half of the
patients received no further omeprazole therapy and the
rest received an additional 7 weeks of omeprazole therapy.
Age, gender, initial diagnosis, site of the lesion, H. pylori
status and smoking habits of all patients were recorded
before the ESD procedure. After the procedure, data re-
garding abdominal pain and bleeding were recorded for
all the patients. The presence of H. pylori infection wasassessed by performing a histological examination and the
rapid urease test using four endoscopic biopsy specimens
(2 from the antrum and 2 from the body of the stomach),
as well as testing for serum H. pylori immunoglobulin G
antibodies. We determined that a patient as had H. pylori
infection when either of these tests was positive. In
addition, we retrospectively analyzed data in the medical
records of these patients. This study was approved by
the Ethics Committee, University of Toyama (Approval
number: Rin-nin No. 22–48).
Evaluation of ulcer healing and symptoms
The size of the ulcer caused by ESD was determined by
measuring the resected specimen as this provided a
more accurate measurement than assessment of the
ulcer in the stomach with an endoscope. Ulcer area was
calculated as the maximum diameter multiplied by the
perpendicular diameter. Follow-up endoscopy was per-
formed at 1 day, 4 weeks, and 8 weeks after ESD. Ulcers
were also staged according to a 6-stage classification sys-
tem proposed by Sakita and Fukutomi (Table 1) [11].
The size of the ulcer at 4 and 8 weeks after ESD was es-
timated from the maximum diameter alone rather than
by multiplying the 2 diameters, because the ulcers had
decreased in size and it was difficult to measure the
smaller perpendicular diameter.
The symptoms of all enrolled patients were evaluated
at 1 week, 4 weeks, and 8 weeks after ESD.
Statistical analysis
Data were analyzed using the Mann–Whitney U-test. To
assess the progress of ulcer healing, Scheffe’s F-test and
repeated calculations of analysis of variance were per-
formed as deemed appropriate. All statistical analyses
were performed using SPSS Statistics for Windows (ver-
sion 19; SPSS Inc., Chicago, IL, USA), and instances with
p of <0.05 were considered to represent statistically sig-
nificant differences.
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A flow diagram shows the disposition of the participants in
this study (Figure 1). A total of 75 patients underwent ESD
for gastric mucosal tumors between June 2005 and July
2006 at Toyama University Hospital. Of these patients, 45
patients met our inclusion criteria and did not meet any of
our exclusion criteria, this including 22 patients who re-
ceived oral omeprazole therapy for 1 week (1-week group)
and 23 patients who received oral omeprazole therapy for
8 weeks (8-week group). The characteristics of the 2 groups
are listed in Table 2. No significant difference was noted be-
tween the groups with regard to gender, age, smoking
habits, H. pylori status, carcinoma/adenoma ratio, tumor
size, size of resected area, or tumor location.
The ulcer stages in each group at 4 and 8 weeks after
ESD are shown in Table 3. There were no active ulcers
in either group at 4 or 8 weeks after ESD. In the 8-week
group, the ulcers were stage H2 in 19 patients (83%) and
S1 in 4 patients (17%) at 4 weeks; that is, 83% of the pa-
tients had unhealed ulcers at this time point. In the
1-week group, the ulcers were stage H1 in 2 patients
(9%), H2 in 12 patients (55%), and S1 in 8 patients (36%)
at 4 weeks; that is, 64% patients had unhealed ulcers at
4 weeks. At 8 weeks after ESD, the ulcers were stage S
(healed) in 22 patients (95.6%) from the 8-week group
and in 20 patients (90.9%) from the 1-week group. There
was no significant difference in the ulcer-healing rate be-
tween the groups at either 4 or 8 weeks after ESD.
The maximum diameter of the ulcers caused by ESD
in both treatment groups at 1 day, 4 weeks, and 8 weeks
after ESD were measured endoscopically. The rate of
ulcer healing was not significantly different between the
groups (Figure 2).
The occurrence of ESD-related abdominal pain and
bleeding, which required endoscopic hemostasis after
ESD, is shown in Table 4. Between 1 and 7 days after theAfter ESD, omeprazole
for 2 days and then o





Patients undergoing ESD for
Figure 1 Flow diagram of the study.ESD, 2 patients in the 8-week group and 1 in the 1-week
group experienced abdominal pain. No patient reported
abdominal pain at 4 or 8 weeks after ESD. Bleeding from
the ulcer was observed in 2 patients in the 8-week group
and in 1 patient in the 1-week group, as assessed by
follow-up endoscopy performed at 1 day after ESD.
These patients underwent hemostasis procedures and
no bleeding was detected afterwards. No patient had
melena, hematemesis, or anemic progression that war-
ranted treatment.
Discussion
This study showed that the quality and rate of healing of
artificial ulcers after ESD were not significantly different
between groups treated for 1 or 8 weeks with oral omep-
razole. This is, to the best of our knowledge, the first re-
port to evaluate an extremely short period (1 week) of
oral PPI administration for treating ESD-induced gastric
ulcers. PPIs have been generally administered to achieve
rapid healing of EMR-induced gastric ulcers [12,13].
In order to accelerate ulcer healing, clot stabilization
through elevation of the intragastric pH is required. A
bolus intravenous injection of PPI followed by continu-
ous infusion can be effective for decreasing the rate of
rebleeding rate in patients who had received successful
endoscopic treatment for bleeding peptic ulcers [14].
However, there has been no consensus about whether
artificial ulcers and peptic ulcers should be similarly
managed. Several studies have suggested that EMR-
induced ulcers heal more easily than peptic ulcers. Lee
et al. compared the healing of small ulcers induced by
conventional EMR after 1 and 4 weeks of the PPI treat-
ment and reported that there was no difference in the
percentage reduction of ulcer size [15]. Therefore, short-
term omeprazole therapy is generally used to treat ulcers
after conventional EMR for gastric lesions. was given intravenously 
rally for 1 week (N=45)





 gastric mucosal tumors (N=75)
Excluded (N=30)
Exclusion criteria (N=30)








Male 19 (82.6%) 19 (86.4%) 0.731
Age, years [mean ± standard
deviation (SD)]
71.1 ± 7.75 68.2 ± 10.3 0.426
Smoker 5 (21.7%) 5 (22.7%) 0.768
Helicobacter pylori positive 16 (69.6%) 18 (81.8%) 0.344
Histopathology
Adenocarcinoma, W/D or M/D† 22 (95.7%) 21 (95.5%) 0.975
Adenoma 1 (4.3%) 1 (4.5%)
Tumor area, mm2 (mean ± SD) 322 ± 317 298 ± 263 0.488
Resected area, mm2 (mean ± SD) 1,014 ± 600 1,027 ± 582 1.000
Location
Upper third 8 (34.8%) 9 (40.9%) 0.807
Mid third 12 (52.2%) 7 (31.8%)
Lower third 3 (13.0%) 6 (27.3%)





















Figure 2 The maximum ulcer diameter (mean ± standard deviation)
at 1 day, 4 weeks and 8 weeks after ESD. There were no significant
differences between the two groups.
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tional EMR—it allows the en bloc resection of small to
large tumors. Therefore, ESD has recently become popu-
lar in Japan, because of which the size of the artificial ul-
cers has increased. The mean diameter of a peptic ulcer
is usually approximately 10–20 mm, which is similar to
the size of the ulcer caused by conventional EMR. Size is
an important determinant of the healing of peptic ulcers.
Ulcer diameter has been reported to predict healing of a
H. pylori-related gastric ulcer within 8 weeks [16-18].
One week of triple-therapy against H. pylori, including
double-dose PPI, was not sufficient treatment for gastric
ulcers that were very large (>15 mm), and these ulcers
required additional treatment to heal [18]. However, arti-
ficial ulcers induced by ESD are usually larger than those
induced by conventional EMR, and a larger ulcer in-
creases the risk of bleeding and requires a longer healingTable 3 Ulcer stages in the 2 groups
8-week
group
N = 23 (%)
1-week
group
N = 22 (%)
P-value*
Ulcer stage After 4 weeks H1 0 (0) 2 (9.1) 0.323
H2 19 (82.6) 12 (54.5)
S1 4 (17.4) 8 (36.4)
S2 0 (0) 0 (0)
After 8 weeks H1 0 (0) 0 (0) 1.000
H2 1 (4.3) 2 (9.1)
S1 21 (91.3) 18 (81.8)
S2 1 (4.3) 2 (9.1)
*Mann–Whitney U test.time [19]. This suggests that the optimum duration of
the PPI treatment after ESD may differ from that after
conventional EMR. Therefore, we investigated the effi-
cacy of 2 PPI regimens in this study. In the conventional
EMR study of Lee et al., the initial mean [± standard de-
viation (SD)] ulcer size was 503.8 (±301.6) mm2 [15],
while the initial mean (±SD) ulcer area was 1027 (±582)
mm2 in our 1-week group. Although the ulcer area in
our study was clearly larger than that in the study of Lee
et al., there was no significant difference in the results of
the 2 studies. This suggested that the potent acid sup-
pression provided by 1 week of oral omeprazole therapy
after 2 days of intravenous omeprazole administration
may be sufficient to heal ESD-induced gastric ulcers.
This result was quite different from previous studies that
showed that the short-term PPI treatment was not suffi-
cient for the healing of larger peptic ulcers [20,21].
Regarding the medication cost, the total cost was 3646
yen for the 1-week group (omeprazole injection for
2 days and tablets for 1 week) and 11,946 yen for the
8-week group (omeprazole injection for 2 days and tab-
lets for 8 weeks). Thus, at only 30% of the cost for the









Patients with pain, N (%)
Within 1 week 2 (8.6) 1 (4.5) 0.581
0 (0) 0 (0) 1.000
After 4–8 weeks 0 (0) 0 (0) 1.000
Bleeding, N (%)
Bleeding† 2 (8.6) 1 (4.5) 0.581
Melena, hematemesis or anemia 0 (0) 0 (0) 1.000
*Mann–Whitney U test.
†Bleeding observed by endoscopy at 1 day after ESD.
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10,000 ESD procedures are performed annually in Japan;
therefore, 83,000,000 yen could be saved every year if
the duration of omeprazole use could be decreased to
1 week from 8 weeks in patients who undergo ESD.
We have also evaluated H. pylori infection status be-
cause infection can influence the quality and speed of
gastric ulcer healing [22]. Kakushima et al. reported that
H. pylori infection status did not affect the healing of
artificial ulcers after ESD [23]. In our study, no correl-
ation was found between H. pylori infection status and
ulcer healing in either group (data not shown).
Only three patients in this study needed urgent endos-
copy for gastric bleeding and the bleeding rate seemed
to be lower than previously reported [10]. This may be
because of recent improvements of hemostasis tech-
niques performed after ESD. However, this study may
have too small of a sample size to robustly evaluate the
risk of bleeding after ESD.
Conclusions
Our results suggested that use of oral omeprazole for
1 week can be sufficient for healing ESD-induced artificial
ulcers. The administration of oral omeprazole for 1 week
after ESD for gastric lesions should also be considered as
it is more cost effective than 8 weeks of treatment. How-
ever, a large-scale prospective clinical trial with a statisti-
cally determined sample size will be required to confirm
these results.
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